Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 8,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

NCT00630331
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
11,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602
View directory record Official record
Conditions
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
Interventions
SLN360, Placebo
Drug
Lead sponsor
Silence Therapeutics plc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 23, 2026, 9:21 AM EDT
Suspended Not applicable Interventional

Vascularized Composite Bladder Allograft Transplantation

NCT05462561
View directory record Official record
Conditions
Neurogenic Bladder, Bladder Dysfunction, Immunosuppression
Interventions
Quality-of-Life Assessment, Robotic Vascularized Composite Bladder Allograft Transplantation
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial Evaluating THB335 in Healthy Participants

NCT06425861
View directory record Official record
Conditions
Healthy
Interventions
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Drug
Lead sponsor
Third Harmonic Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

NCT04116073
View directory record Official record
Conditions
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Interventions
INCMGA00012 (PD-1 antibody)
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

NCT00363142
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
Half-boosted Fosamprenavir, Full Boosted Fosamprenavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 23, 2026, 9:21 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT04291105
View directory record Official record
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Interventions
VV1, Cemiplimab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 9:21 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551
View directory record Official record
Conditions
HIV Infections
Interventions
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths

NCT00107042
View directory record Official record
Conditions
Hepatitis B
Interventions
Recombivax, Twinrix
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 17 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Not applicable Interventional

Human-Animal Interaction to Promote Recovery Following Pediatric Brain Injury

NCT04016961
View directory record Official record
Conditions
Brain Injuries, Acquired Brain Injury, Traumatic Brain Injury
Interventions
AAT - Dog, TAU - No Dog
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

NCT02073656
View directory record Official record
Conditions
Hepatitis C Virus, HIV
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

NCT01632527
View directory record Official record
Conditions
Age Related Macular Degeneration, Macular Degeneration, AMD
Interventions
HuCNS-SC cells
Drug
Lead sponsor
StemCells, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Oct 23, 2026, 9:21 AM EDT
Completed No phase listed Observational

Clinical IGSP-CHOP Boston

NCT00428831
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751
View directory record Official record
Conditions
Influenza
Interventions
MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitization Study of ATx201 in Healthy Volunteers

NCT03375957
View directory record Official record
Conditions
Sensitivity, Contact
Interventions
ATx201, ATx201 Placebo Gel
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 23, 2026, 9:21 AM EDT
Active, not recruiting Phase 1 Interventional

CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS

NCT05306457
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNS10-NPC-GDNF
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Results available

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

NCT00426556
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Everolimus, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
11
States / cities
*see Various Departments*, California • Fountain Valley, California • Loma Linda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT04795037
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo
Drug
Lead sponsor
Curacle Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

NCT05074472
View directory record Official record
Conditions
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
Interventions
ZB131
Drug
Lead sponsor
ZielBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

NCT02952729
View directory record Official record
Conditions
Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer, Advanced Gastric Cancer
Interventions
XMT-1522
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

NCT01561937
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
warfarin, eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 23, 2026, 9:21 AM EDT
Completed Not applicable Interventional Results available

The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination

NCT01009645
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message, Control Educational Message
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 23, 2026, 9:21 AM EDT